Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Progen's PI-88 misses NSCLC endpoint

Progen (ASX:PGL; PGLA) said PI-88 plus docetaxel missed the primary endpoint of

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE